The fate of this year's Bledisloe Cup has already been decided but Australia captain Michael Hooper wants his side to look at Saturday's clash with New Zealand in Yokohama as a chance to lay down a marker for next year's Rugby World Cup.
Reported by RTE.ie 1 hour ago.
Hooper wants Wallabies to lay down All Blacks marker
↧
↧
Sport24.co.za | Faf: We won't sledge Aussies over ball-tampering
Proteas captain Faf du Plessis says there will be one unmentionable when it comes to sledging Australia in the upcoming limited overs series.
Reported by News24 1 hour ago.
↧
Sport24.co.za | Gillespie eyes Australian selector role
Former Test fast bowler Jason Gillespie revealed his ambition to become a selector on Friday as Australia rebuilds after this year's ball-tampering scandal.
Reported by News24 1 hour ago.
↧
Australia: Cross-border restructuring conundrum: The current position for restructuring professionals following The OJSC International Bank of Azerbaijan (IBA Case) - Norton Rose Fulbright Australia
The article considers the impact of the IBA case for restructuring professionals, in Singapore, Hong Kong and Australia.
Reported by Mondaq 1 hour ago.
↧
Meghan Markle blue dress: The Duchess of Sussex makes subtle alteration to Veronica Beard shirt dress in Tonga to avoid breaking royal protocol
Meghan Markle wore a Veronica Beard blue dress in Tonga [Getty] Meghan Markle has been non-stop while on the royal tour with Prince Harry, where the Duke and Duchess of Sussex are visiting Australia, Fiji, Tonga and New Zealand. Meghan – who announced she’s pregnant with her first baby earlier this month – has been attending couple's events, public gatherings are parties, wearing a collection of stunning maternity outfits. For Meghan and Harry’s second day in ...
Reported by OK! 34 minutes ago.
↧
↧
LaserShip to Sponsor EDWINS Leadership & Restaurant Institute’s 3rd Annual 5K Grind: Run for Re-Entry
Annual event supports previously incarcerated citizens for their right for fair and equal futures.
VIENNA, Va. (PRWEB) October 26, 2018
LaserShip, an e-commerce parcel carrier servicing the Eastern and Midwest U.S., will participate in EDWINS Leadership & Restaurant Institute’s 3rd Annual 5K Grind: Run for Re-Entry as a Forefront Sponsor. The $2,500 contribution supports citizens returning from incarceration and their right for fair and equal futures. The third annual event takes place this Sunday, Oct. 28 in Cleveland, Ohio.
“EDWINS is fortunate to have the support of LaserShip for our 5K Grind. This is our 3rd Annual Run for Re-entry and we are going to have the toughest race in Cleveland,” says Brandon E. Chrostowski, founder and president of EDWINS. “Not only will this event raise awareness for re-entry issues, but the difficulty of the course reflects the challenges that returning citizens face every day. LaserShip’s sponsorship shows returning citizens that they are truly cared for by their community.”
EDWINS Leadership & Restaurant Institute is a non-profit organization that gives formerly incarcerated adults a foundation in the culinary and hospitality industry while providing support needed for long-term success. The organization’s mission is to teach a skilled trade in the culinary arts, empower a passion for hospitality management and prepare its students for a successful transition. In 2016, LaserShip celebrated 30 years of service by donating $5,000 to EDWINS Leadership & Restaurant Institute. Chrostowski was nominated for CNN’s Hero of the Year award in 2016.
“EDWINS is an incredible organization that not only helps provide the support returning citizens need, but also sheds light on the importance of giving people a second chance,” says Blake Averill, CEO of LaserShip. “We are incredibly excited to be supporting this event and the organization’s mission.”
The 5K, presented in partnership with Running Forward and Giving Back, begins at 10 a.m. EDT at Shaker Square. To learn more about EDWINS or to register for the event, visit https://www.edwinsrestaurant.org. For more information about LaserShip, visit https://www.lasership.com.
About LaserShip, Inc.:
LaserShip is an e-commerce delivery company that provides last-mile solutions for shippers that desire reduced transit times and increased flexibility within their supply chain. Founded in 1986, LaserShip has evolved into the leading provider of same-day and next-day delivery services in the eastern and Midwest U.S. for premier e-commerce and product-supply business, including five of the largest retailers in the U.S. LaserShip also provides delivery solutions for critical and time-sensitive shipments in North America, Europe, Asia, Australia, and select destinations in South America and the Middle East through its Global Critical Delivery division. For more information, visit lasership.com. Reported by PRWeb 1 hour ago.
VIENNA, Va. (PRWEB) October 26, 2018
LaserShip, an e-commerce parcel carrier servicing the Eastern and Midwest U.S., will participate in EDWINS Leadership & Restaurant Institute’s 3rd Annual 5K Grind: Run for Re-Entry as a Forefront Sponsor. The $2,500 contribution supports citizens returning from incarceration and their right for fair and equal futures. The third annual event takes place this Sunday, Oct. 28 in Cleveland, Ohio.
“EDWINS is fortunate to have the support of LaserShip for our 5K Grind. This is our 3rd Annual Run for Re-entry and we are going to have the toughest race in Cleveland,” says Brandon E. Chrostowski, founder and president of EDWINS. “Not only will this event raise awareness for re-entry issues, but the difficulty of the course reflects the challenges that returning citizens face every day. LaserShip’s sponsorship shows returning citizens that they are truly cared for by their community.”
EDWINS Leadership & Restaurant Institute is a non-profit organization that gives formerly incarcerated adults a foundation in the culinary and hospitality industry while providing support needed for long-term success. The organization’s mission is to teach a skilled trade in the culinary arts, empower a passion for hospitality management and prepare its students for a successful transition. In 2016, LaserShip celebrated 30 years of service by donating $5,000 to EDWINS Leadership & Restaurant Institute. Chrostowski was nominated for CNN’s Hero of the Year award in 2016.
“EDWINS is an incredible organization that not only helps provide the support returning citizens need, but also sheds light on the importance of giving people a second chance,” says Blake Averill, CEO of LaserShip. “We are incredibly excited to be supporting this event and the organization’s mission.”
The 5K, presented in partnership with Running Forward and Giving Back, begins at 10 a.m. EDT at Shaker Square. To learn more about EDWINS or to register for the event, visit https://www.edwinsrestaurant.org. For more information about LaserShip, visit https://www.lasership.com.
About LaserShip, Inc.:
LaserShip is an e-commerce delivery company that provides last-mile solutions for shippers that desire reduced transit times and increased flexibility within their supply chain. Founded in 1986, LaserShip has evolved into the leading provider of same-day and next-day delivery services in the eastern and Midwest U.S. for premier e-commerce and product-supply business, including five of the largest retailers in the U.S. LaserShip also provides delivery solutions for critical and time-sensitive shipments in North America, Europe, Asia, Australia, and select destinations in South America and the Middle East through its Global Critical Delivery division. For more information, visit lasership.com. Reported by PRWeb 1 hour ago.
↧
Offer document regarding Nasdaq Technology’s recommended public cash offer to shareholders and warrant holders in Cinnober made public
*THIS PRESS RELEASE MAY NOT BE, DIRECTLY OR INDIRECTLY, DISTRIBUTED OR PUBLISHED TO OR WITHIN AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND OR SOUTH AFRICA. THE OFFER IS NOT BEING MADE TO (NOR WILL TENDER OF SHARES BE ACCEPTED FROM) PERSONS IN THESE COUNTRIES OR PERSONS IN ANY OTHER COUNTRIES WHERE TENDER OF SHARES WOULD REQUIRE FURTHER DOCUMENTATION, FILINGS OR OTHER ACTIONS IN ADDITION TO SWEDISH LAW.*NEW YORK and STOCKHOLM, Sweden, Oct. 26, 2018 (GLOBE NEWSWIRE) -- On 14 September 2018, Nasdaq Technology AB^1^) (“*Nasdaq Technology*”), a wholly-owned indirect subsidiary of Nasdaq, Inc.,^2^) announced a recommended public cash offer to the shareholders and warrant holders in Cinnober Financial Technology Aktiebolag (”*Cinnober*”) to acquire all outstanding shares and warrants in Cinnober at a price of SEK 75 per share and SEK 85 per warrant (the ”*Offer*”).The offer document is available at Nasdaq, Inc.’s transaction website (http://ir.nasdaq.com/acquisitions/validation-access-rights) and at SEB’s website for prospectuses and offer documents (www.sebgroup.com/prospectuses). The offer document, an acceptance form and a self-addressed envelope will be distributed to shareholders that were owner-registered shareholders in Cinnober on 26 October 2018 as well as to the warrant holders.
The acceptance period for the Offer runs from 29 October 2018 to 14 December 2018 (subject to any extension thereof). Settlement is expected to commence around 21 December 2018, subject to the conditions for completion having been fulfilled or if Nasdaq Technology otherwise decides to complete the Offer.
*For additional information, please contact:*
*Nasdaq, Inc.*
Ryan Wells, Principal, Corporate Communications
Phone: +44 (0) 7809 596 390
Email: ryan.wells@nasdaq.comErik Granström, Corporate Communication, Sweden
Phone: +46 8 405 78 07
Email: erik.granstrom@nasdaq.comEd Ditmire, Vice President, Investor Relations
Phone: +1 (212) 4018737
Email: ed.ditmire@nasdaq.com
*Information is also available at Nasdaq, Inc.’s website, http://ir.nasdaq.com/acquisitions/validation-access-rights**.*
Nasdaq Technology discloses the information provided herein pursuant to the Takeover Rules for certain trading platforms issued by the Swedish Corporate Governance Board 1 April 2018. This information was submitted for announcement on 26 October 2018 at 11.00 a.m. (CET).
_________________________
*IMPORTANT INFORMATION*
This press release has been published in Swedish and English. In the event of any discrepancy between the Swedish original version and the English translation, the Swedish original version shall prevail.
The Offer, pursuant to the terms and conditions presented in this press release, is not being made to persons whose participation in the Offer requires that an additional offer document is prepared or registration effected or that any other measures are taken in addition to those required under Swedish laws and regulations.
This press release and any related Offer documentation are not being distributed and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any additional measures to be taken or would be in conflict with any law or regulation in such country – any such action will not be permitted or sanctioned by Nasdaq Technology. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions may be disregarded.
The Offer is being made in the United States in accordance with the provisions of Regulation 14E promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”) and the exemptions provided by Rule 14d-1(c) promulgated under the Exchange Act, and otherwise in accordance with Swedish law and practice. Accordingly, the Offer is subject to disclosure and other procedural requirements, including with respect to the offer duration and settlement that are different from those applicable under U.S. domestic tender offer procedures and laws. U.S. holders of the Shares are encouraged to consult with their legal, financial and tax advisors regarding the Offer. For purposes of the Offer, “United States” and “U.S.” means the United States of America (its territories and possessions, all states of the Unites States of America and the District of Columbia).
It may be difficult for U.S. holders to enforce their rights and any claim arising out of U.S. securities laws, since Nasdaq Technology and the Company are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a U.S. or non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment.
The Offer is not being and will not be made, directly or indirectly, in or into, or by use of mail or any other means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of Australia, Hong Kong, Japan, Canada, New Zealand or South Africa. This includes, but is not limited to facsimile transmission, e-mail, telex, telephone, the internet and other forms of electronic transmission. The Offer cannot be accepted and shares may not be tendered in the Offer by any such use, means, instrumentality or facility of, or from Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or by persons located or resident in those jurisdictions. Accordingly, this press release and any related Offer documentation are not being and should not be mailed or otherwise transmitted, distributed, forwarded or sent in or into Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or to any Australian, Hong Kongese, Japanese, Canadian, New Zealander or South African or any persons located or resident in Australia, Hong Kong, Japan, Canada, New Zealand or South Africa.
Any purported tender of shares in an Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported tender of shares made by a person located in Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or any agent, fiduciary or other intermediary acting on a non-discretionary basis for a principal giving instructions from within Australia, Hong Kong, Japan, Canada, New Zealand or South Africa will be invalid and will not be accepted. Each holder of shares participating in the Offer will represent that it is not an Australian, Hong Kongese, Japanese, Canadian, New Zealander or South African, is not located or resident in Australia, Hong Kong, Japan, Canada, New Zealand or South Africa and is not participating in such Offer from Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or that it is acting on a non-discretionary basis for a principal that is not an Australian, Hong Kongese, Japanese, Canadian, New Zealand or South African, that is located outside Australia, Hong Kong, Japan, Canada, New Zealand or South Africa and that is not giving an order to participate in such offer from those jurisdictions. Nasdaq Technology will not deliver any consideration from the Offer into Australia, Hong Kong, Japan, Canada, New Zealand or South Africa.
Notwithstanding the above, Nasdaq Technology, its advisors, brokers or other persons that act as intermediaries for, or by instructions from, Nasdaq Technology, may, in accordance with, and considering the limitations that follow by the Takeover Rules, applicable laws and other regulations, take actions with the purpose to acquire additional shares in Cinnober, including acquisitions on the open market at current prices or in private transactions at negotiated prices. Such acquisitions, or actions made with the purpose of acquiring shares in Cinnober, may potentially be made up until the end of the acceptance period and after completion of the Offer. Any such acquisitions will be made in accordance with applicable laws, rules and regulations. No such acquisitions may be made at prices that are higher than the consideration that is offered in the Offer, or on terms that are more beneficial than the terms of the Offer, unless the value and other terms of the Offer are adjusted accordingly.
*Forward-looking information*
Statements in this press release relating to future status and circumstances, including statements regarding the anticipated offer timeline, future performance, growth and other projections as well as benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Actual results may differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Nasdaq Technology or Nasdaq, Inc. Such risk factors may include performance of the global economy, ability of Nasdaq Technology and Nasdaq, Inc. to integrate the acquired business, ability of Nasdaq Technology and Nasdaq, Inc. to receive regulatory approvals necessary for the Offer (whether timely or otherwise) and availability of exemptions from under Rule 14d-1(c) or Rule 14d-1(d) promulgated under the Exchange Act, among others. Any such forward-looking statements speak only as of the date on which they were made and Nasdaq Technology and Nasdaq, Inc. have no obligation (and undertake no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for as required by applicable laws and regulations.
___________________________
^1^) “Nasdaq Technology” refers to the Swedish private limited liability company, Nasdaq Technology AB, reg. no. 556314-8138, with the address Tullvaktsvägen 15, SE-105 78 Stockholm, Sweden.
^2^) ”Nasdaq, Inc.” refers to Nasdaq, Inc., a Delaware corporation whose shares are the Nasdaq Stock Market in New York, and traded under the symbol NDAQ, with the address One Liberty Plaza, New York, NY 10006, United States. Reported by GlobeNewswire 1 hour ago.
The acceptance period for the Offer runs from 29 October 2018 to 14 December 2018 (subject to any extension thereof). Settlement is expected to commence around 21 December 2018, subject to the conditions for completion having been fulfilled or if Nasdaq Technology otherwise decides to complete the Offer.
*For additional information, please contact:*
*Nasdaq, Inc.*
Ryan Wells, Principal, Corporate Communications
Phone: +44 (0) 7809 596 390
Email: ryan.wells@nasdaq.comErik Granström, Corporate Communication, Sweden
Phone: +46 8 405 78 07
Email: erik.granstrom@nasdaq.comEd Ditmire, Vice President, Investor Relations
Phone: +1 (212) 4018737
Email: ed.ditmire@nasdaq.com
*Information is also available at Nasdaq, Inc.’s website, http://ir.nasdaq.com/acquisitions/validation-access-rights**.*
Nasdaq Technology discloses the information provided herein pursuant to the Takeover Rules for certain trading platforms issued by the Swedish Corporate Governance Board 1 April 2018. This information was submitted for announcement on 26 October 2018 at 11.00 a.m. (CET).
_________________________
*IMPORTANT INFORMATION*
This press release has been published in Swedish and English. In the event of any discrepancy between the Swedish original version and the English translation, the Swedish original version shall prevail.
The Offer, pursuant to the terms and conditions presented in this press release, is not being made to persons whose participation in the Offer requires that an additional offer document is prepared or registration effected or that any other measures are taken in addition to those required under Swedish laws and regulations.
This press release and any related Offer documentation are not being distributed and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any additional measures to be taken or would be in conflict with any law or regulation in such country – any such action will not be permitted or sanctioned by Nasdaq Technology. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions may be disregarded.
The Offer is being made in the United States in accordance with the provisions of Regulation 14E promulgated under the Securities Exchange Act of 1934 (the “Exchange Act”) and the exemptions provided by Rule 14d-1(c) promulgated under the Exchange Act, and otherwise in accordance with Swedish law and practice. Accordingly, the Offer is subject to disclosure and other procedural requirements, including with respect to the offer duration and settlement that are different from those applicable under U.S. domestic tender offer procedures and laws. U.S. holders of the Shares are encouraged to consult with their legal, financial and tax advisors regarding the Offer. For purposes of the Offer, “United States” and “U.S.” means the United States of America (its territories and possessions, all states of the Unites States of America and the District of Columbia).
It may be difficult for U.S. holders to enforce their rights and any claim arising out of U.S. securities laws, since Nasdaq Technology and the Company are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a U.S. or non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment.
The Offer is not being and will not be made, directly or indirectly, in or into, or by use of mail or any other means or instrumentality of interstate or foreign commerce of, or any facilities of a national securities exchange of Australia, Hong Kong, Japan, Canada, New Zealand or South Africa. This includes, but is not limited to facsimile transmission, e-mail, telex, telephone, the internet and other forms of electronic transmission. The Offer cannot be accepted and shares may not be tendered in the Offer by any such use, means, instrumentality or facility of, or from Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or by persons located or resident in those jurisdictions. Accordingly, this press release and any related Offer documentation are not being and should not be mailed or otherwise transmitted, distributed, forwarded or sent in or into Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or to any Australian, Hong Kongese, Japanese, Canadian, New Zealander or South African or any persons located or resident in Australia, Hong Kong, Japan, Canada, New Zealand or South Africa.
Any purported tender of shares in an Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported tender of shares made by a person located in Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or any agent, fiduciary or other intermediary acting on a non-discretionary basis for a principal giving instructions from within Australia, Hong Kong, Japan, Canada, New Zealand or South Africa will be invalid and will not be accepted. Each holder of shares participating in the Offer will represent that it is not an Australian, Hong Kongese, Japanese, Canadian, New Zealander or South African, is not located or resident in Australia, Hong Kong, Japan, Canada, New Zealand or South Africa and is not participating in such Offer from Australia, Hong Kong, Japan, Canada, New Zealand or South Africa or that it is acting on a non-discretionary basis for a principal that is not an Australian, Hong Kongese, Japanese, Canadian, New Zealand or South African, that is located outside Australia, Hong Kong, Japan, Canada, New Zealand or South Africa and that is not giving an order to participate in such offer from those jurisdictions. Nasdaq Technology will not deliver any consideration from the Offer into Australia, Hong Kong, Japan, Canada, New Zealand or South Africa.
Notwithstanding the above, Nasdaq Technology, its advisors, brokers or other persons that act as intermediaries for, or by instructions from, Nasdaq Technology, may, in accordance with, and considering the limitations that follow by the Takeover Rules, applicable laws and other regulations, take actions with the purpose to acquire additional shares in Cinnober, including acquisitions on the open market at current prices or in private transactions at negotiated prices. Such acquisitions, or actions made with the purpose of acquiring shares in Cinnober, may potentially be made up until the end of the acceptance period and after completion of the Offer. Any such acquisitions will be made in accordance with applicable laws, rules and regulations. No such acquisitions may be made at prices that are higher than the consideration that is offered in the Offer, or on terms that are more beneficial than the terms of the Offer, unless the value and other terms of the Offer are adjusted accordingly.
*Forward-looking information*
Statements in this press release relating to future status and circumstances, including statements regarding the anticipated offer timeline, future performance, growth and other projections as well as benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Actual results may differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Nasdaq Technology or Nasdaq, Inc. Such risk factors may include performance of the global economy, ability of Nasdaq Technology and Nasdaq, Inc. to integrate the acquired business, ability of Nasdaq Technology and Nasdaq, Inc. to receive regulatory approvals necessary for the Offer (whether timely or otherwise) and availability of exemptions from under Rule 14d-1(c) or Rule 14d-1(d) promulgated under the Exchange Act, among others. Any such forward-looking statements speak only as of the date on which they were made and Nasdaq Technology and Nasdaq, Inc. have no obligation (and undertake no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for as required by applicable laws and regulations.
___________________________
^1^) “Nasdaq Technology” refers to the Swedish private limited liability company, Nasdaq Technology AB, reg. no. 556314-8138, with the address Tullvaktsvägen 15, SE-105 78 Stockholm, Sweden.
^2^) ”Nasdaq, Inc.” refers to Nasdaq, Inc., a Delaware corporation whose shares are the Nasdaq Stock Market in New York, and traded under the symbol NDAQ, with the address One Liberty Plaza, New York, NY 10006, United States. Reported by GlobeNewswire 1 hour ago.
↧
Meghan Markle and Prince Harry's plan forced to abort Sydney landing
The charter jet carrying Harry and Meghan back to Australia aborted the landing upon approach at Sydney Airport. Its pilot explained that another plane on the runway had been 'slow to roll'.
Reported by MailOnline 1 hour ago.
↧
Sport24.co.za | Crutchlow crash mars Australia Moto GP practice
Italy's Andrea Iannone clocked the fastest time in practice on Friday ahead of the Australian Moto GP in a fiercely competitive session marred by a heavy crash.
Reported by News24 37 minutes ago.
↧
↧
Opthea Reports Positive Three-Month Data from Phase 1b Dose Escalation Study for OPT-302 in Diabetic Macular Edema
MELBOURNE, Australia, Oct. 26, 2018 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT), a clinical-stage biopharmaceutical company developing innovative biologic therapies to treat retinal diseases, today announced positive data from the Phase 1b dose escalation study of OPT-302 for patients with diabetic macular edema (DME). The study evaluated three escalating dose levels of OPT-302 (0.3, 1.0 or 2.0 mg), a novel VEGF-C/D ‘Trap’ therapy, in combination with aflibercept (Eylea^®, 2.0 mg) administered once every 4 weeks for a total of 3 intravitreal injections in 9 patients with persistent central-involved DME despite sub-optimal responses to standard of care anti-VEGF-A therapy.
Eyes with persistent DME sub-responsive to multiple prior anti-VEGF-A injections demonstrated visual and anatomic improvement at 12 weeks following conversion to OPT-302 combination treatment. A dose-response relationship of increased gains in visual acuity (VA) was shown with ascending dose levels of OPT-302 combination treatment which also produced reductions in retinal swelling.
“Alternative approaches such as combination therapies are needed for treating patients with DME who have persistent macula swelling and vision loss despite treatment with standard of care,” says David Boyer, MD, Clinical Professor of Ophthalmology at USC/Keck School of Medicine and principal investigator on the trial. “I am highly encouraged by the evidence of efficacy and continued favourable safety profile for OPT-302 combination therapy which has potential to benefit the many diabetic patients who have limited responses to anti-VEGF-A treatment.”
Patients enrolled in the study had a history of diabetes with a mean duration of 14.1 years and persistent DME despite receiving a mean of 6.3 prior anti-VEGF-A injections. The mean change at week 12 from baseline in best corrected VA (BCVA) across all OPT-302 combination therapy dose groups was a gain of +7.7 letters (baseline of 65 letters) with a corresponding mean reduction in central subfield thickness (CST) of -71 µM (baseline of 434 µm). A dose-response relationship of improved visual acuity at all time-points from baseline to week 12 was demonstrated with ascending dose levels of combination treatment with BCVA gains of +3.0, +5.7 and +14.3 letters seen at 0.3 mg, 1.0 mg and 2.0 mg of OPT-302 respectively. A similar dose-response was observed in the proportion of patients gaining ≥ 5 letters in BCVA, with 33% (1/3), 67% (2/3) and 100% (3/3) of patients gaining 5 or more letters in each of the respective 0.3, 1.0 and 2.0 mg dose levels of OPT-302 in combination with aflibercept (2.0 mg).
Bilateral disease was present in 5 of the 9 patients with both eyes previously treated with anti-VEGF-A therapy for persistent DME (mean of 6 prior injections in both eyes) providing a within patient comparison of the study eye which received OPT-302 + aflibercept combination therapy and the fellow eye which continued on anti-VEGF-A monotherapy (aflibercept or ranibizumab). Combination therapy with OPT-302 + ranibizumab in the study eye had greater improvements than the anti-VEGF-A monotherapy in the fellow eye for mean change from baseline to week 12 in BCVA of +10 letter gain (baseline of 63 letters) versus +2.6 letters (baseline of 73 letters) respectively and central subfield thickness reduction of -80 µm (baseline of 445 µm) versus -6 µm (baseline of 389 µm). In addition, 3/5 (60%) study eyes receiving OPT-302 combination therapy had a ≥ 50% reduction in excess foveal thickness, a measure of macular swelling, compared to 1/5 (20%) of fellow eyes that were administered anti-VEGF-A monotherapy.
The demonstration of a dose response relationship for OPT-302 combination treatment to improve visual acuity in patients with persistent DME in the Phase 1b study together with biological responses on anatomic measures in both DME and wet AMD lesions indicates that pan-VEGF (A, C and D) inhibition may offer benefits that exceed the inhibition of VEGF-A alone. OPT-302 combination therapy achieves more complete suppression of the VEGF/VEGFR pathway by blocking all members of the VEGF family of growth factors, including VEGF-A, VEGF-C and VEGF-D.
Dr Megan Baldwin, CEO and Managing Director of Opthea, commented “We are very encouraged by the results of this Phase 1b dose escalation study in patients with persistent DME. Together with previously reported results from our Phase 1/2a trial in wet AMD patients, we have now demonstrated a well-tolerated safety profile of OPT-302 in combination with aflibercept and ranibizumab (Lucentis^®) and promising signs of clinical activity in both wet AMD and DME patients. Our data suggests that VEGF-C/D blockade may provide additional clinical benefit over standard of care anti-VEGF-A therapy. To that end, we look forward to reporting outcomes from our two international, multicentre Phase 2 trials that are currently ongoing and actively recruiting patients with newly diagnosed wet AMD and persistent DME despite prior anti-VEGF-A therapy.”
OPT-302 + aflibercept intravitreal injections were well tolerated at all dose levels throughout week 12. No treatment-related ocular or systemic adverse events were observed throughout the week 12 timepoint, and the very few ocular events noted were mild and primarily related to the intravitreal injection procedure.
The Company’s multi-centre Phase 2a randomised, controlled dose expansion trial is now actively recruiting patients with persistent DME. Patients in the Phase 2a study are randomised in a 2:1 ratio to receive either OPT-302 (2 mg) + aflibercept (2 mg) or aflibercept monotherapy by intravitreal injection once every 4 weeks for 3 doses. Enrolment in the Phase 2a trial is progressing at U.S. and Australian sites with primary data anticipated in 2H’ 2019.
The Phase 1b DME study results were presented at the Ophthalmology Innovation Summit (OIS), held in conjunction with the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago on Thursday, October 25^th, 2018 (US Central Daylight Time). Additional meeting information is available at https://ois.net/ois-aao-2018/ and a copy of the OIS presentation is available on Opthea’s website at www.opthea.com.
Additional information on Opthea’s technology and clinical trials in wet AMD and diabetic macular edema (DME) can be found at www.opthea.com and ClinicalTrials.gov (ID#: NCT03345082 and ID#: NCT03397264, respectively).
*About OPT-302*
OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF-C and VEGF-D) that cause blood vessels to grow and leak, processes which contribute to the pathophysiology of retinal diseases. Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A (eg. Lucentis^®/Eylea^®). Combination therapy of OPT-302 and a VEGF-A inhibitor achieves more complete blockade of members of the VEGF family, blocks mechanisms contributing to sub-optimal response to selective VEGF-A inhibitors and has the potential to improve vision outcomes by more completely inhibiting the pathways involved in disease progression.
Opthea has completed a Phase 1/2a clinical trial in the US investigating OPT-302 wet AMD patients as a monotherapy and in combination with Lucentis^®. The trial was conducted under an FDA approved IND at 14 US clinical sites. The purpose of the trial was to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis^® in patients with wet age related macular degeneration (AMD). Of the 51 patients enrolled, 25 were treatment naïve and 26 had received prior intravitreal anti-VEGF-A therapy.
Further details on Opthea’s clinical trials can be found at www.clinicaltrials.gov, clinical trial identifiers: NCT02543229 (Phase 1/2a wet AMD); NCT03345082 (Phase 2b wet AMD) and NCT03397264 (Phase 1b/2a DME). Additional information on Opthea’s technology and clinical trials can found on Opthea’s website www.opthea.com.
*About DME and Wet AMD *
DME is the leading cause of blindness in diabetics and is estimated to affect approximately 2 million people globally^1,2,3. Chronically elevated blood glucose levels in Type 1 and Type 2 diabetics can lead to inflammation, vascular dysfunction and hypoxia, causing upregulation of members of the VEGF family of growth factors. VEGFs, including VEGF-A and VEGF-C, stimulate vascular permeability or vascular leakage, leading to fluid accumulation in the macula at the back of the eye and retinal thickening which affects vision. Existing standard of care treatments for DME are limited and include inhibitors of VEGF-A (Lucentis^®, Eylea^®), steroids and laser therapy. Despite these treatments, many patients remain refractory and have a sub-optimal response to therapy with persistent fluid and impaired vision. OPT-302 blocks VEGF-C and VEGF-D, which cause vessels to grow and leak. Used in combination with a VEGF-A inhibitor, OPT-302 has the potential to improve clinical outcomes in DME patients.
Wet (neovascular) age-related macular degeneration, or wet AMD, is a disease characterised by the loss of vision of the middle of the visual field caused by degeneration of the central portion of the retina (the macula). Abnormal growth of blood vessels below the retina, and the leakage of fluid and protein from the vessels, causes retinal degeneration and leads to severe and rapid loss of vision. Wet AMD is the leading cause of blindness in the developed world in individuals aged 50 years or older. The prevalence of AMD is increasing annually as the population ages. Without treatment, wet AMD patients often experience a chronic, rapid decline in visual acuity and increase in retinal fluid.
Existing standard of care treatments for DME and wet AMD include agents that inhibit VEGF-A, but not VEGF-C or VEGF-D. Sales of the drug Lucentis^® (Roche/Novartis), which targets VEGF-A, were over $US3.4BN in 2017. Sales of Eylea^® (Regeneron/Bayer), which also targets VEGF-A but not VEGF-C/-D were over $US5.9BN in 2017. Many patients receiving Lucentis^®/Eylea^® are classified as non-responders or ‘poor’ responders and do not experience a significant gain in vision and/or have persistent retinal vascular leakage. There is great opportunity to improve patient responses by targeting more than one factor involved in disease progression. Existing therapies, such as Lucentis^® and Eylea^®, target VEGF-A that promotes blood vessel growth and leakage through its receptor VEGFR-2. VEGF-C can also induce angiogenesis and vessel leakage through the same receptor as well as through an independent pathway. Combined inhibition of VEGF-A and VEGF-C/-D, has the potential to improve patient response by more effective inhibition of the pathways involved in disease progression.
*About Opthea Limited*
Opthea (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGFR-3. Opthea’s intellectual property is held within its wholly-owned subsidiary Vegenics Pty Ltd. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Opthea’s product development programs are focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for ‘back of the eye’ disease such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
*Inherent risks of Investment in Biotechnology Companies*
There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Thus investment in companies specialising in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.
*Forward-looking statements*
Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services. Opthea undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.
^1. Ding J, Wong TY. Curr Diab Rep. 12: 346-354, 2012.
^2. Lee R, Wong TY, Sabanayagam C. Eye and Vision. 2:17, 2015.
^3. Managing Diabetic Eye Disease in Clinical Practice. Singh RP (ed). Springer International Publishing 2015.
Company & Media Enquiries: Join our email database to receive program updates:
Megan Baldwin, PhD
CEO & Managing Director
Opthea Limited
Tel: +61 (0) 447 788 674
megan.baldwin@opthea.com
Australia:
Rudi Michelson
Monsoon Communications
Tel: +61 (0) 3 9620 3333 Tel: +61 (0) 3 9826 0399
info@opthea.com
www.opthea.com
U.S.A. & International:
Jason Wong
Blueprint Life Science Group
Tel: +1 415 375 3340, Ext 4
Jwong@bplifescience.com Reported by GlobeNewswire 38 minutes ago.
Eyes with persistent DME sub-responsive to multiple prior anti-VEGF-A injections demonstrated visual and anatomic improvement at 12 weeks following conversion to OPT-302 combination treatment. A dose-response relationship of increased gains in visual acuity (VA) was shown with ascending dose levels of OPT-302 combination treatment which also produced reductions in retinal swelling.
“Alternative approaches such as combination therapies are needed for treating patients with DME who have persistent macula swelling and vision loss despite treatment with standard of care,” says David Boyer, MD, Clinical Professor of Ophthalmology at USC/Keck School of Medicine and principal investigator on the trial. “I am highly encouraged by the evidence of efficacy and continued favourable safety profile for OPT-302 combination therapy which has potential to benefit the many diabetic patients who have limited responses to anti-VEGF-A treatment.”
Patients enrolled in the study had a history of diabetes with a mean duration of 14.1 years and persistent DME despite receiving a mean of 6.3 prior anti-VEGF-A injections. The mean change at week 12 from baseline in best corrected VA (BCVA) across all OPT-302 combination therapy dose groups was a gain of +7.7 letters (baseline of 65 letters) with a corresponding mean reduction in central subfield thickness (CST) of -71 µM (baseline of 434 µm). A dose-response relationship of improved visual acuity at all time-points from baseline to week 12 was demonstrated with ascending dose levels of combination treatment with BCVA gains of +3.0, +5.7 and +14.3 letters seen at 0.3 mg, 1.0 mg and 2.0 mg of OPT-302 respectively. A similar dose-response was observed in the proportion of patients gaining ≥ 5 letters in BCVA, with 33% (1/3), 67% (2/3) and 100% (3/3) of patients gaining 5 or more letters in each of the respective 0.3, 1.0 and 2.0 mg dose levels of OPT-302 in combination with aflibercept (2.0 mg).
Bilateral disease was present in 5 of the 9 patients with both eyes previously treated with anti-VEGF-A therapy for persistent DME (mean of 6 prior injections in both eyes) providing a within patient comparison of the study eye which received OPT-302 + aflibercept combination therapy and the fellow eye which continued on anti-VEGF-A monotherapy (aflibercept or ranibizumab). Combination therapy with OPT-302 + ranibizumab in the study eye had greater improvements than the anti-VEGF-A monotherapy in the fellow eye for mean change from baseline to week 12 in BCVA of +10 letter gain (baseline of 63 letters) versus +2.6 letters (baseline of 73 letters) respectively and central subfield thickness reduction of -80 µm (baseline of 445 µm) versus -6 µm (baseline of 389 µm). In addition, 3/5 (60%) study eyes receiving OPT-302 combination therapy had a ≥ 50% reduction in excess foveal thickness, a measure of macular swelling, compared to 1/5 (20%) of fellow eyes that were administered anti-VEGF-A monotherapy.
The demonstration of a dose response relationship for OPT-302 combination treatment to improve visual acuity in patients with persistent DME in the Phase 1b study together with biological responses on anatomic measures in both DME and wet AMD lesions indicates that pan-VEGF (A, C and D) inhibition may offer benefits that exceed the inhibition of VEGF-A alone. OPT-302 combination therapy achieves more complete suppression of the VEGF/VEGFR pathway by blocking all members of the VEGF family of growth factors, including VEGF-A, VEGF-C and VEGF-D.
Dr Megan Baldwin, CEO and Managing Director of Opthea, commented “We are very encouraged by the results of this Phase 1b dose escalation study in patients with persistent DME. Together with previously reported results from our Phase 1/2a trial in wet AMD patients, we have now demonstrated a well-tolerated safety profile of OPT-302 in combination with aflibercept and ranibizumab (Lucentis^®) and promising signs of clinical activity in both wet AMD and DME patients. Our data suggests that VEGF-C/D blockade may provide additional clinical benefit over standard of care anti-VEGF-A therapy. To that end, we look forward to reporting outcomes from our two international, multicentre Phase 2 trials that are currently ongoing and actively recruiting patients with newly diagnosed wet AMD and persistent DME despite prior anti-VEGF-A therapy.”
OPT-302 + aflibercept intravitreal injections were well tolerated at all dose levels throughout week 12. No treatment-related ocular or systemic adverse events were observed throughout the week 12 timepoint, and the very few ocular events noted were mild and primarily related to the intravitreal injection procedure.
The Company’s multi-centre Phase 2a randomised, controlled dose expansion trial is now actively recruiting patients with persistent DME. Patients in the Phase 2a study are randomised in a 2:1 ratio to receive either OPT-302 (2 mg) + aflibercept (2 mg) or aflibercept monotherapy by intravitreal injection once every 4 weeks for 3 doses. Enrolment in the Phase 2a trial is progressing at U.S. and Australian sites with primary data anticipated in 2H’ 2019.
The Phase 1b DME study results were presented at the Ophthalmology Innovation Summit (OIS), held in conjunction with the annual meeting of the American Academy of Ophthalmology (AAO) in Chicago on Thursday, October 25^th, 2018 (US Central Daylight Time). Additional meeting information is available at https://ois.net/ois-aao-2018/ and a copy of the OIS presentation is available on Opthea’s website at www.opthea.com.
Additional information on Opthea’s technology and clinical trials in wet AMD and diabetic macular edema (DME) can be found at www.opthea.com and ClinicalTrials.gov (ID#: NCT03345082 and ID#: NCT03397264, respectively).
*About OPT-302*
OPT-302 is a soluble form of vascular endothelial growth factor receptor 3 (VEGFR-3) or ‘Trap’ molecule that blocks the activity of two proteins (VEGF-C and VEGF-D) that cause blood vessels to grow and leak, processes which contribute to the pathophysiology of retinal diseases. Opthea is developing OPT-302 for use in combination with inhibitors of VEGF-A (eg. Lucentis^®/Eylea^®). Combination therapy of OPT-302 and a VEGF-A inhibitor achieves more complete blockade of members of the VEGF family, blocks mechanisms contributing to sub-optimal response to selective VEGF-A inhibitors and has the potential to improve vision outcomes by more completely inhibiting the pathways involved in disease progression.
Opthea has completed a Phase 1/2a clinical trial in the US investigating OPT-302 wet AMD patients as a monotherapy and in combination with Lucentis^®. The trial was conducted under an FDA approved IND at 14 US clinical sites. The purpose of the trial was to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis^® in patients with wet age related macular degeneration (AMD). Of the 51 patients enrolled, 25 were treatment naïve and 26 had received prior intravitreal anti-VEGF-A therapy.
Further details on Opthea’s clinical trials can be found at www.clinicaltrials.gov, clinical trial identifiers: NCT02543229 (Phase 1/2a wet AMD); NCT03345082 (Phase 2b wet AMD) and NCT03397264 (Phase 1b/2a DME). Additional information on Opthea’s technology and clinical trials can found on Opthea’s website www.opthea.com.
*About DME and Wet AMD *
DME is the leading cause of blindness in diabetics and is estimated to affect approximately 2 million people globally^1,2,3. Chronically elevated blood glucose levels in Type 1 and Type 2 diabetics can lead to inflammation, vascular dysfunction and hypoxia, causing upregulation of members of the VEGF family of growth factors. VEGFs, including VEGF-A and VEGF-C, stimulate vascular permeability or vascular leakage, leading to fluid accumulation in the macula at the back of the eye and retinal thickening which affects vision. Existing standard of care treatments for DME are limited and include inhibitors of VEGF-A (Lucentis^®, Eylea^®), steroids and laser therapy. Despite these treatments, many patients remain refractory and have a sub-optimal response to therapy with persistent fluid and impaired vision. OPT-302 blocks VEGF-C and VEGF-D, which cause vessels to grow and leak. Used in combination with a VEGF-A inhibitor, OPT-302 has the potential to improve clinical outcomes in DME patients.
Wet (neovascular) age-related macular degeneration, or wet AMD, is a disease characterised by the loss of vision of the middle of the visual field caused by degeneration of the central portion of the retina (the macula). Abnormal growth of blood vessels below the retina, and the leakage of fluid and protein from the vessels, causes retinal degeneration and leads to severe and rapid loss of vision. Wet AMD is the leading cause of blindness in the developed world in individuals aged 50 years or older. The prevalence of AMD is increasing annually as the population ages. Without treatment, wet AMD patients often experience a chronic, rapid decline in visual acuity and increase in retinal fluid.
Existing standard of care treatments for DME and wet AMD include agents that inhibit VEGF-A, but not VEGF-C or VEGF-D. Sales of the drug Lucentis^® (Roche/Novartis), which targets VEGF-A, were over $US3.4BN in 2017. Sales of Eylea^® (Regeneron/Bayer), which also targets VEGF-A but not VEGF-C/-D were over $US5.9BN in 2017. Many patients receiving Lucentis^®/Eylea^® are classified as non-responders or ‘poor’ responders and do not experience a significant gain in vision and/or have persistent retinal vascular leakage. There is great opportunity to improve patient responses by targeting more than one factor involved in disease progression. Existing therapies, such as Lucentis^® and Eylea^®, target VEGF-A that promotes blood vessel growth and leakage through its receptor VEGFR-2. VEGF-C can also induce angiogenesis and vessel leakage through the same receptor as well as through an independent pathway. Combined inhibition of VEGF-A and VEGF-C/-D, has the potential to improve patient response by more effective inhibition of the pathways involved in disease progression.
*About Opthea Limited*
Opthea (ASX:OPT) is a biologics drug developer focusing on ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGFR-3. Opthea’s intellectual property is held within its wholly-owned subsidiary Vegenics Pty Ltd. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Opthea’s product development programs are focused on developing OPT-302 (formerly VGX-300, soluble VEGFR-3) for ‘back of the eye’ disease such as wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
*Inherent risks of Investment in Biotechnology Companies*
There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Opthea are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Thus investment in companies specialising in drug development must be regarded as highly speculative. Opthea strongly recommends that professional investment advice be sought prior to such investments.
*Forward-looking statements*
Certain statements in this ASX announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services. Opthea undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Actual results could differ materially from those discussed in this ASX announcement.
^1. Ding J, Wong TY. Curr Diab Rep. 12: 346-354, 2012.
^2. Lee R, Wong TY, Sabanayagam C. Eye and Vision. 2:17, 2015.
^3. Managing Diabetic Eye Disease in Clinical Practice. Singh RP (ed). Springer International Publishing 2015.
Company & Media Enquiries: Join our email database to receive program updates:
Megan Baldwin, PhD
CEO & Managing Director
Opthea Limited
Tel: +61 (0) 447 788 674
megan.baldwin@opthea.com
Australia:
Rudi Michelson
Monsoon Communications
Tel: +61 (0) 3 9620 3333 Tel: +61 (0) 3 9826 0399
info@opthea.com
www.opthea.com
U.S.A. & International:
Jason Wong
Blueprint Life Science Group
Tel: +1 415 375 3340, Ext 4
Jwong@bplifescience.com Reported by GlobeNewswire 38 minutes ago.
↧
Australia: The burning issue of regulatory action in Victoria and NSW for aluminium composite panel cladding (ACP) - Carroll & O'Dea
The article looks at recent legislative reforms that have been proposed in NSW and Victoria surrounding the use of ACP.
Reported by Mondaq 36 minutes ago.
↧
Steve Smith makes it to AFR Young Rich list despite ball-tampering scare
[Australia], Oct 26 (ANI): Former Australian skipper Steve Smith has made it to the 2018 Australian Financial Review (AFP) Young Rich List for the first time despite being handed over a one-year
Reported by Sify 33 minutes ago.
↧
Australia: Avopiling Pty Ltd v Bosevski; Avopiling Pty Ltd v The Workers Compensation Nominal Insurer - Carroll & O'Dea
This case highlights issues in the preparation of pleadings and calculation of damages in personal injury litigation.
Reported by Mondaq 19 minutes ago.
↧
↧
Hardman & Co Research: SatoshiPay: An emerging leader in digital nanopayments
Hardman & Co Research
26-Oct-2018 / 10:59 GMT/BST
--------------------
*Hardman & Co Research: An emerging leader in digital nanopayments*
SatoshiPay is a developer of micropayment solutions for the digital economy. Its blockchain-based platform facilitates payments of small, even fractional, sums for online content and services. This delivers a much-needed monetisation platform for publishers against a backdrop of pressure on digital advertising revenue.
THIS DOCUMENT IS NOT AVAILABLE FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA, OR TO ANY U.S. PERSON, NOR TO PARTIES WHO ARE NOT CONSIDERED 'RELEVANT PERSONS' IN THE UNITED KINGDOM, NOR SHOULD IT BE TAKEN, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, TO EITHER OF THESE CATEGORIES. THIS DOCUMENT HAS BEEN FURNISHED TO YOU SOLELY FOR YOUR INFORMATION.
Please click here for the full report:
https://www.hardmanandco.com/research/corporate-research/an-emerging-leader-in-digital-nanopayments/
*To contact us:*
Hardman & Co
35 New Broad Street
London
EC2M 1NH
www.hardmanandco.com
*Follow us on Twitter* @HardmanandCo *Contacts:*
Milan Radia
+44 (0) 20 7194 7622
mr@hardmanandco.com
*Hardman & Co Research can still be accessed for free after MiFID II. Please *click here* to read the statement.*
*About Hardman & Co:* For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
--------------------
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
--------------------
End of Announcement - EQS News Service Reported by EQS Group 4 minutes ago.
26-Oct-2018 / 10:59 GMT/BST
--------------------
*Hardman & Co Research: An emerging leader in digital nanopayments*
SatoshiPay is a developer of micropayment solutions for the digital economy. Its blockchain-based platform facilitates payments of small, even fractional, sums for online content and services. This delivers a much-needed monetisation platform for publishers against a backdrop of pressure on digital advertising revenue.
THIS DOCUMENT IS NOT AVAILABLE FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, NEW ZEALAND OR THE REPUBLIC OF SOUTH AFRICA, OR TO ANY U.S. PERSON, NOR TO PARTIES WHO ARE NOT CONSIDERED 'RELEVANT PERSONS' IN THE UNITED KINGDOM, NOR SHOULD IT BE TAKEN, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, TO EITHER OF THESE CATEGORIES. THIS DOCUMENT HAS BEEN FURNISHED TO YOU SOLELY FOR YOUR INFORMATION.
Please click here for the full report:
https://www.hardmanandco.com/research/corporate-research/an-emerging-leader-in-digital-nanopayments/
*To contact us:*
Hardman & Co
35 New Broad Street
London
EC2M 1NH
www.hardmanandco.com
*Follow us on Twitter* @HardmanandCo *Contacts:*
Milan Radia
+44 (0) 20 7194 7622
mr@hardmanandco.com
*Hardman & Co Research can still be accessed for free after MiFID II. Please *click here* to read the statement.*
*About Hardman & Co:* For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.
Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.
--------------------
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
--------------------
End of Announcement - EQS News Service Reported by EQS Group 4 minutes ago.
↧
Hollysys Automation Technologies to Announce Fiscal Year 2019 First Quarter Financial Results and Host Earnings Conference Call on November 13, 2018 US ET
BEIJING, Oct. 26, 2018 /PRNewswire/ --* Hollysys Automation Technologies Ltd. (NASDAQ: HOLI) ("Hollysys" or the "Company")*, a leading provider of automation and control technologies and applications in China, today announced that it will report its financial results for fiscal year 2019 first quarter on Tuesday, November 13, 2018 U.S. Eastern Time.The Company will host a conference call at 8:00 pm November 13, 2018 U.S. Eastern Time / 9:00 am November 14, 2018 Beijing Time, to discuss the financial results for fiscal year 2019 first quarter ended September 30, 2018 and business outlook.
To participate, please call the following numbers ten minutes before the scheduled start of the call. The conference call identification number is *6498818.*
*Standard International Dial-In Number:*
+65 67135090
*Participant Local Dial-In Numbers:*
Australia, Sydney
+61 290833212
China, Domestic
4006208038
China, Domestic
8008190121
Hong Kong
+852 30186771
Japan, Tokyo
+81 345036012
Korea (South), Seoul
+82 27395177
Taiwan, Taipei
+886 255723895
United Kingdom, London
+44 2036214779
United States, New York
+1 8456750437
*Participant ITFS Dial-In Numbers:*
Australia
1300717205
Australia
1800411623
Belgium
080071900
Canada
18663861016
France
0800912761
Germany
08001820671
Hong Kong
800906601
India
180030105440
Indonesia, PT Indosat access
0018030179156
Indonesia, PT Telkom access
0078030179156
Italy
800874737
Japan
0120925376
Korea (South), Domestic
0808500474
Malaysia
1800820152
Netherlands
08000221931
New Zealand
0800880084
Norway
80010719
Philippines
180016120306
Switzerland
0800561006
Taiwan
0809091568
Thailand
001800656772
United Kingdom
08082346646
United States
18665194004
In addition, a recording of the conference call will be accessible within 48 hours via Hollysys' website at: http://hollysys.investorroom.com
*About Hollysys Automation Technologies Ltd. (NASDAQ: HOLI)*
Hollysys Automation Technologies is a leading provider of automation and control technologies and applications in China that enables its diversified industry and utility customers to improve operating safety, reliability, and efficiency. Founded in 1993, Hollysys has approximately 3,300 employees with nationwide presence in over 60 cities in China, with subsidiaries and offices in Singapore, Malaysia, Dubai, India, and serves over 10,000 customers more than 30,000 projects in the industrial, railway, subway & nuclear industries in China, South-East Asia, and the Middle East. Its proprietary technologies are applied in its industrial automation solution suite including DCS (Distributed Control System), PLC (Programmable Logic Controller), RMIS (Real-time Management Information System), HAMS (HolliAS Asset Management System), OTS (Operator Training System), HolliAS BATCH (Batch Application Package), HolliAS APC Suite (Advanced Process Control Package), SIS (Safety Instrumentation System), high-speed railway signaling system of TCC (Train Control Center), ATP (Automatic Train Protection), Subway Supervisory and Control platform, SCADA (Supervisory Control and Data Acquisition), nuclear power plant automation and control system and other products.
*SAFE HARBOUR:*
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, involve known and unknown risks and uncertainties. Such forward-looking statements, based upon the current beliefs and expectations of Hollysys' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward looking statements. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
*For further information, please contact:*
Hollysys Automation Technologies Ltd.
www.hollysys.com
+8610-58981386
investors@hollysys.com
View original content:http://www.prnewswire.com/news-releases/hollysys-automation-technologies-to-announce-fiscal-year-2019-first-quarter-financial-results-and-host-earnings-conference-call-on-november-13-2018-us-et-300738564.html
Related Links :
http://www.hollysys.com Reported by PR Newswire Asia 3 minutes ago.
↧
Finch replaces Paine as Australia ODI captain
Aaron Finch will captain Australia in their one-day international series against South Africa in November, replacing Tim Paine.
Reported by BBC Sport 2 hours ago.
↧
New Zealand beats Australia 37-20 in Bledisloe 3
YOKOHAMA, Japan (AP) — New Zealand beat Australia 37-20 in the third Bledisloe Cup test at Nissan Stadium Saturday to sweep the series 3-0:___New Zealand 37 (Liam Squire, Kieran Read, Beauden Barrett, Ben Smith, Rieko Ioane tries;...
Reported by New Zealand Herald 2 hours ago.
↧
↧
Marquez claims pole for Australian GP
PHILLIP ISLAND, Australia (AP) — Honda rider Marc Marquez continued his dominance of the Moto GP championship by claiming pole position at the Australian GP on Saturday.After clinching his seventh world title with victory in Japan...
Reported by New Zealand Herald 2 hours ago.
↧
PGA Tour WGC- HSBC Champions Scores
Oct 27 (OPTA) - Scores from the PGA Tour WGC- HSBC Champions on Saturday -13 Tony Finau (USA) 66 67 70 -10 Patrick Reed (USA) 64 72 70 Justin Rose (England) 69 67 70 Xander Schauffele (USA) 66 71 69 -8 Tommy Fleetwood (England) 68 68 72 Andrew Putnam (USA) 70 71 67 -7 Kiradech Aphibarnrat (Thailand) 68 71 70 Keegan Bradley (USA) 69 70 70 -6 Jason Day (Australia)
Reported by Reuters India 1 hour ago.
↧
Boys in blue salute 'best of the best'
The Godolphin trainer delivered the appraisal after Australia's darling of the turf etched her name into the record books as a four-time Cox Plate winner.
Reported by Brisbane Times 1 hour ago.
↧
More Pages to Explore .....
